SVB Leerink analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and lowers the price target from $85 to $81.
Analyst Ratings For C3.ai
Within the last quarter, C3.ai (NYSE:AI) has observed the following analyst ratings:
SVB Leerink Maintains Underperform on Moderna, Lowers Price Target to $81
SVB Leerink analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and lowers the price target from $85 to $81.
Related Posts
B of A Securities Downgrades Baxter Intl to Neutral, Announces $55 Price Target
B of A Securities analyst Travis Steed downgrades Baxter Intl (NYSE:BAX) from Buy to Neutral and announces $55 price target.
Here Are The Total Savings If You Bought Your House In December, Instead Of October
This year has been a bear on the mortgage market as the average interest rate for the most popular long-term mortgage — 30-year fixed — is more than double what it was a year ago.
Reported Late Monday Feb 6, T-Mobile Agrees To Sell $3B Of Senior Notes In Response To Earlier Announcement Of A Registered Public Offering
T-Mobile US, Inc. (NASDAQ:TMUS) ("T-Mobile") announced today that T-Mobile USA, Inc., its direct wholly-owned subsidiary ("T-Mobile USA" or the "Issuer"), has agreed to